갑상선유두상암 환자에서 말초혈액의 종양표지자와 임상 소견과의 상관관계
Correlation between Tumor Markers and Clinicopathologic Factors in Peripheral Blood of Papillary Thyroid Cancer Patients
1
조회
0
다운로드
0
인용
0
참고문헌
초록
Vascular endothelial growth factor (VEGF), matrix metalloproteinase-9 (MMP-9), hepatocyte growth factor (HGF) and epidermal growth factor (EGF) are involved in the pathogenesis and development of thyroid cancer. The purpose of this study was to find the correlation between serum VEGF, VEGF-C, MMP-9, EGF, HGF and clinicopathologic factors. Subjects and Method：Using enzyme linked immunosorbent assay (ELISA) kit, 64 patients with thyroid papillary cancer, 15 benign thyroid mass patients and 14 healthy normal control were analyzed to investigate the expression of human VEGF, VEGF-C, MMP-9, EGF and HGF. Results：There were no significant differences in the serum levels of VEGF, VEGFC, MMP-9, TGF, EGF between papillary thyroid cancer group and the benign thyroid tumor group. Levels of VEGF and MMP- 9 appeared higher in lateral cervical lymph node metastasis than N0 lymph node metastasis or only cervical component lymph node metastasis. But, the serum VEGF-C level was significantly related with tumor size, T stage, extrathyroidal extension and lateral cervical lymph node metastasis (p=0.043). Conclusion : VEGF, VEGF-C, MMP-9, HGF and EGF could not be used as a diagnostic tool for differentiating malignancy from benign thyroid disease. Serum VEGF, VEGF-C and MMP-9 levels were correlated with lateral cervical lymph node metastasis of papillary thyroid cancer. Consequently, this results suggests that they may serve as preoperative supplementary marker for determining the extent of papillary thyroid cancer surgery. Also, serum VEGF-C levels were correlated with some prognostic factors of papillary thyroid cancer. (Korean J Otorhinolaryngol-Head Neck Surg 2008;51:812-8)
Abstract
Vascular endothelial growth factor (VEGF), matrix metalloproteinase-9 (MMP-9), hepatocyte growth factor (HGF) and epidermal growth factor (EGF) are involved in the pathogenesis and development of thyroid cancer. The purpose of this study was to find the correlation between serum VEGF, VEGF-C, MMP-9, EGF, HGF and clinicopathologic factors. Subjects and Method：Using enzyme linked immunosorbent assay (ELISA) kit, 64 patients with thyroid papillary cancer, 15 benign thyroid mass patients and 14 healthy normal control were analyzed to investigate the expression of human VEGF, VEGF-C, MMP-9, EGF and HGF. Results：There were no significant differences in the serum levels of VEGF, VEGFC, MMP-9, TGF, EGF between papillary thyroid cancer group and the benign thyroid tumor group. Levels of VEGF and MMP- 9 appeared higher in lateral cervical lymph node metastasis than N0 lymph node metastasis or only cervical component lymph node metastasis. But, the serum VEGF-C level was significantly related with tumor size, T stage, extrathyroidal extension and lateral cervical lymph node metastasis (p=0.043). Conclusion : VEGF, VEGF-C, MMP-9, HGF and EGF could not be used as a diagnostic tool for differentiating malignancy from benign thyroid disease. Serum VEGF, VEGF-C and MMP-9 levels were correlated with lateral cervical lymph node metastasis of papillary thyroid cancer. Consequently, this results suggests that they may serve as preoperative supplementary marker for determining the extent of papillary thyroid cancer surgery. Also, serum VEGF-C levels were correlated with some prognostic factors of papillary thyroid cancer. (Korean J Otorhinolaryngol-Head Neck Surg 2008;51:812-8)
참고문헌 (19)
- DeGroot LJ, "Nature history, treatment, and course of papillary thyroid carcinoma", J Clin Endocrinol Metab, 71(2), pp.414~424 (1990)
- Hanahan D, "Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis", Cell, 86(3), pp.353~364 (1996)
- Poon RT, "Clinical implications of circulating angiogenic factors in cancer patients", J Clin Oncol, 19(4), pp.1207~1225 (2001)
- Ferrara N, "Vascular endothelial growth factor: Basic science and clinical progress", Endocr Rev, 25(4), pp.581~611 (2004)
- Yu XM, "Increased expression of vascular endothelial growth factor C in papillary thyroid carcinoma correlates with cervical lymph node metastases", Clin cancer Res, 11(22), pp.8063~8069 (2005)
- Wang TB, "Association of serum vascular endothelial growth factor-C and lymphatic vessel density with lymph node metastasis and prognosis of patients with gastric cancer", World J Gastroenterol, 13(12), pp.1794~1797 (2007)
- Soh EY, "Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid", J Clin Endocrinol Metab, 82(11), pp.3741~3747 (1997)
- Lennard CM, "Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer", Surgery, 129(5), pp.552~558 (2001)
- Yu XM, "Increased expression of vascular endothelial growth factor C in papillary thyroid carcinoma correlates with cervical lymph node metastases", Clin Cancer Res, 11(22), pp.8063~8069 (2005)
- Bunone G, "Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features", Am J Pathol, 155(6), pp.1967~1976 (1999)
- Kraiem Z, "Matrix metalloproteinases and the thyroid", Thyroid, 10(12), pp.1061~1069 (2000)
- Klein M, "Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma", J Clin Endocrinol Metab, 86(2), pp.656~658 (2001)
- Eccles N, "Mitogenic stimulation of normal and oncogene-transformed human thyroid epithelial cells by hepatocyte growth factor", Mol Cell Endocrinol, 117(2), pp.247~251 (1996)
- Sheen-Chen SM, "Serum levels of hepatocyte growth factor in patients with breast cancer", Cancer Epidemiol Biomarkers Prev, 14(3), pp.715~717 (2005)
- Vesely D, "Serum levels of IGF-I, HGF, TGF beta1, bFGF and VEGF in thyroid gland tumors", Physiol Res, 53(1), pp.83~89 (2004)
- Konturek A, "Significance of vascular endothelial growth factor and epidermal growth factor in development of papillary thyroid", Langenbecks Arch Surg, 390(3), pp.216~221 (2005)
- Pasieka Z, "Evaluation of the level of bFGF, VEGF, sICAM-1, and sVCAM-1 in serum of patients thyroid cancer", Recent Results Cancer Res, 162, pp.189~194 (2003)
- Lin SY, "Preoperative plasma concentrations of vascular endothelial growth factor and matrix metalloproteinase 9 are associated with stage progression in papillary thyroid cancer", Clin Endocrinol, 58(4), pp.513~518 (2003)
- 백승국, "갑상선 유두상 암종에서의 COX-2와 VEGF-C의 발현과 예후인자들과의 관계", 대한이비인후과학회지 두경부외과학, 47(12), pp.1273~1277 (2004), 대한이비인후과학회